Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aldeyra Therapeutics (ALDX)
NASDAQ:ALDX
RESEARCH TOOLSreports
ALDX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.71 - $6.92
Previous CloseN/A
Volume102.94K
Average Volume (3M)347.39K
Market Cap
$393.62M
Enterprise Value$126.91M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.72
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding59,549,600
10 Day Avg. Volume408,886
30 Day Avg. Volume347,389
Standard Deviation0.25
R-Squared0.08
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-12.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-482.94
Enterprise Value/Ebitda-2.98
Forecast
1Y Price Target
$11.50Price Target Upside71.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Aldeyra Therapeutics News
PremiumCompany Announcements
Aldeyra Therapeutics Announces Executive Team Changes
PremiumCompany Announcements
Aldeyra Therapeutics Announces Major Dry Eye Treatment Success
PremiumCompany Announcements
Aldeyra Therapeutics Completes Phase 3 Trial Enrollment for Reproxalap---
Bulls Say, Bears Say
Bulls Say
Business PartnershipAbbVie is expected to exercise the option to co-commercialize Reproxalap, which includes up to $300M in regulatory and commercial milestones.
Regulatory ApprovalThe FDA has accepted the resubmission of Reproxalap NDA, with a high probability of approval based on recent positive data for dry eye symptoms.
Bears Say
Market CompetitionGiven the availability of generic Restasis, payors may require step-through protocols.
---
Ownership Overview
19.01% Insiders
11.13% Mutual Funds
26.63% Other Institutional Investors
34.30% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALDX FAQ
What was Aldeyra Therapeutics’s price range in the past 12 months?
Aldeyra Therapeutics lowest stock price was $2.71 and its highest was $6.92 in the past 12 months.
What is Aldeyra Therapeutics’s market cap?
Aldeyra Therapeutics’s market cap is $393.62M.
When is Aldeyra Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aldeyra Therapeutics’s earnings last quarter?
Aldeyra Therapeutics released its earnings results on Mar 07, 2024. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.111 by $0.031.
Is Aldeyra Therapeutics overvalued?
According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued.
Does Aldeyra Therapeutics pay dividends?
Aldeyra Therapeutics does not currently pay dividends.
What is Aldeyra Therapeutics’s EPS estimate?
Aldeyra Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aldeyra Therapeutics have?
Aldeyra Therapeutics has 59,549,600 shares outstanding.
What happened to Aldeyra Therapeutics’s price movement after its last earnings report?
Aldeyra Therapeutics reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.111. Following the earnings report the stock price went up 0.238%.
Which hedge fund is a major shareholder of Aldeyra Therapeutics?
Currently, no hedge funds are holding shares in ALDX
---
Aldeyra Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.50 (71.13% Upside)
$11.50 (71.13% Upside)
Blogger Sentiment
Bullish
ALDX Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $10.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
88.85%
12-Months-Change
Fundamentals
Return on Equity
-43.05%
Trailing 12-Months
Asset Growth
-20.34%
Trailing 12-Months
Company Description
Aldeyra Therapeutics
Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
---
ALDX Stock 12 Month Forecast
Average Price Target
$11.50
▲(71.13% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Xoma
―
Ocular Therapeutix
―
Adverum Biotechnologies
―
Kodiak Sciences
―
Best Analysts Covering ALDX
1 Year
1 Year Success Rate
10/15 ratings generated profit
1 Year Average Return
+44.63%
reiterated a buy rating 4 months ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +44.63% per trade.
---